Important COVID-19 updates and latest data
Keeping patients safe
Find alerts, policies and guidance to keep transplant patients safe and reduce the risk for disease transmission here:
Patient safety resources
PDDTE policy changes – effective 9/1/2016
- Policy notice
- Pathogens of special interest
- FDA-cleared assays, used to determine toxoplasmosis immune status or diagnosis
- Zika virus information for organ donation and transplant professionals (7/2016)
- Frequently asked questions about the 2013 PHS guideline
- West Nile Virus risk factors and evaluating potential living donors
- Recognizing central nervous system infections in potential deceased organ donors
- HTLV-1 screening and confirmation in potential donors and reporting potential HTLV-1 infection
- Recognizing seasonal and geographically endemic infections in organ donors; considerations during living donor evaluation
- OPTN policy 5: organ offers, acceptance, and verification (6/2016)
- System changes related to ABO verification policy are now in place (6/2016)
- OPO Pre-Recovery Verification Template (added 6/28/2016)
- ABO Subtyping Organ Donors for Blood Groups A and AB
- Living Donor OR Verification template (revised 5/2017)
- Recipient OR Verification template (revised 5/2017)
- ABO donor recipient compatibility chart (added 4/2016)
- Electronic Medical Record (EMR) suggested data fields (revised 5/2016)
- Update for OPOs about TransNet labels for extra vessels (12/4/2018)
- OPOs must use sterile internal labels for extra vessels beginning 9/1/2015 (Updated 2/1/2019)
- Policy 16: Organ and Vessel Packaging, Labeling, Shipping, and Storage
- Guidance regarding handling and repackaging vessels
Labels (begin using on Mar. 1, 2021)
Root cause analysis
Important patient safety notices
The OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC) is evaluating this situation as it develops.
In order to address patient safety concerns, the OPTN Executive Committee approved a modification of OPTN Policy 6.4: Adult and Pediatric Status Exceptions on July 11 that is now in effect.
This new policy will allow transplant programs to submit an exception request on behalf of adult heart transplant candidates for a Status 1, 2 or 3 exception without requiring hospitalization if the FDA has recalled their implanted mechanical circulatory support device.
Implementation notice: Pre-transplant HIV, HBV and HCV testing requirement updated for candidates younger than age 12
Effective July 1, testing no longer required for HIV, HBV and HCV at the time of hospital admission for transplant candidates younger than age 12.
Contact your individual supplier for more information.
If your institution has stock from the affected lot, please contact your supplier.
If your institution has stock from any of the affected lots, please contact your supplier.
Tests authorized by the FDA to analyze lower respiratory tract specimens.
Committee honored for big ideas and out of the box thinking that has made a significant impact on transplantation.
It is very rare for patients receiving transplants to have a donor-derived disease transmission, according to a recently published study.